918 results on '"Lack, Gideon"'
Search Results
2. Peanut-specific IgG subclasses as biomarkers of peanut allergy in LEAP study participants
3. World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) guidelines update – XVI - Nutritional management of cow's milk allergy
4. Skin as the target for allergy prevention and treatment
5. Awareness and Application of United States Food Allergy Prevention Guidelines Among Pediatricians and Other Clinicians
6. World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) guideline update – XII – Recommendations on milk formula supplements with and without probiotics for infants and toddlers with CMA
7. HLA-associated outcomes in peanut oral immunotherapy trials identify mechanistic and clinical determinants of therapeutic success.
8. Partial Egg Consumption Modifies the Diagnostic Performance of Allergy Tests to Predict Outcome of Double-Blind Placebo-Controlled Food Challenges to Egg
9. Prevention Is Better than Cure: Impact of Allergen Immunotherapy on the Progression of Airway Disease
10. World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) guidelines update – X – Breastfeeding a baby with cow's milk allergy
11. Ara h 2 Peptide Mix Improves the Diagnosis of Peanut Allergy and Is Relevant for Ara h 2–Induced Mast Cell Activation
12. Developing a Prediction Model for Determination of Peanut Allergy Status in the Learning Early About Peanut Allergy (LEAP) Studies
13. Relationships between food allergy and other atopy
14. Ara h 2-Specific IgE Presence Rather Than Its Function Is the Best Predictor of Mast Cell Activation in Children
15. World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) guideline update – XIII – Oral immunotherapy for CMA – Systematic review
16. World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow’s Milk Allergy (DRACMA) Guideline update – XIV – Recommendations on CMA immunotherapy
17. Combining Allergen Components Improves the Accuracy of Peanut Allergy Diagnosis
18. The Ratio Of Ara h 2-Specific IgE At 60 Months Of Age Relative To Earlier Samples May Be A Valuable Biomarker For Predicting Outcomes Of Oral Peanut Challenge At 60 months: Analysis Of Selected Samples From The LEAP Study.
19. An Unintentional Randomized Trial of Early Environmental Exposure to Peanut: The Younger Siblings of LEAP Participants
20. Basophil Activation Test Reduces Oral Food Challenges to Nuts and Sesame
21. Ara h 2 is the dominant peanut allergen despite similarities with Ara h 6
22. Biomarkers of severity and threshold of allergic reactions during oral peanut challenges
23. Defining challenge-proven coexistent nut and sesame seed allergy: A prospective multicenter European study
24. Topical steroid withdrawal and atopic dermatitis
25. Partial egg consumption modifies the diagnostic performance of allergy tests to predict outcome of double-blind placebo-controlled food challenges to egg
26. Biomarkers to predict changes in peanut allergy in children over time
27. World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) guidelines update – X – Breastfeeding a baby with cow's milk allergy
28. EAACI guidelines on the diagnosis of IgE‐mediated food allergy
29. PREVENTION IS BETTER THAN CURE: IMPACT OF ALLERGEN IMMUNOTHERAPY ON THE PROGRESSION OF AIRWAY DISEASE
30. Challenges experienced with early introduction and sustained consumption of allergenic foods in the Enquiring About Tolerance (EAT) study: A qualitative analysis
31. Factors influencing adherence in a trial of early introduction of allergenic food
32. Efficacy of the Enquiring About Tolerance (EAT) study among infants at high risk of developing food allergy
33. Randomized Trial of Peanut Consumption in Infants at Risk for Peanut Allergy
34. Food Allergy: Challenges with the New Guidelines
35. Association of Staphylococcus aureus colonization with food allergy occurs independently of eczema severity
36. Report from the National Institute of Allergy and Infectious Diseases workshop on “Atopic dermatitis and the atopic march: Mechanisms and interventions”
37. Preventing Peanut Allergy: Where Are We Now?
38. Optimising the management of peanut allergy by targeting immune plasticity.
39. Phase 1 trial supports safety and mechanism of action of peptide immunotherapy for peanut allergy.
40. Basophil activation test as predictor of severity and threshold of allergic reactions to egg.
41. Basophil activation test as predictor of severity and threshold of allergic reactions to egg
42. Topical steroid withdrawal and atopic dermatitis
43. HLA alleles and sustained peanut consumption promote IgG4 responses in subjects protected from peanut allergy
44. The global impact of the DRACMA guidelines cow’s milk allergy clinical practice
45. Developing a Prediction Model for Determination of Peanut Allergy Status in the Learning Early About Peanut Allergy (LEAP) Studies
46. Incorporating genetics in identifying peanut allergy risk and tailoring allergen immunotherapy: A perspective on the genetic findings from the LEAP trial
47. Epidermal differentiation complex genetic variation in atopic dermatitis and peanut allergy
48. EAACI Molecular Allergology User's Guide 2.0
49. EAACI guidelines on the diagnosis of IgE-mediated food allergy
50. EAACI Molecular Allergology User's Guide 2.0
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.